{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T02:31:13Z","timestamp":1784341873025,"version":"3.55.0"},"reference-count":32,"publisher":"American Society for Microbiology","issue":"5","license":[{"start":{"date-parts":[[2017,4,24]],"date-time":"2017-04-24T00:00:00Z","timestamp":1492992000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"name":"Paratek Pharmaceuticals"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2017,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            The\n            <jats:italic>in vitro<\/jats:italic>\n            activity and\n            <jats:italic>in vivo<\/jats:italic>\n            efficacy of omadacycline (OMC) were evaluated against the causative pathogens of anthrax and plague,\n            <jats:named-content content-type=\"genus-species\">Bacillus anthracis<\/jats:named-content>\n            and\n            <jats:named-content content-type=\"genus-species\">Yersinia pestis<\/jats:named-content>\n            , respectively. MICs of OMC were determined by broth microdilution according to CLSI guidelines for 30 isolates each of\n            <jats:named-content content-type=\"genus-species\">Y. pestis<\/jats:named-content>\n            and\n            <jats:named-content content-type=\"genus-species\">B. anthracis<\/jats:named-content>\n            . The\n            <jats:italic>in vivo<\/jats:italic>\n            efficacy of omadacycline was studied at a range of dosages in both a postexposure prophylaxis (PEP) murine model of anthrax and plague as well as in a delayed treatment model of inhalational anthrax. Omadacycline was active\n            <jats:italic>in vitro<\/jats:italic>\n            against\n            <jats:named-content content-type=\"genus-species\">Y. pestis<\/jats:named-content>\n            (MIC\n            <jats:sub>90<\/jats:sub>\n            of 1 \u03bcg\/ml) and\n            <jats:named-content content-type=\"genus-species\">B. anthracis<\/jats:named-content>\n            (MIC\n            <jats:sub>90<\/jats:sub>\n            of 0.06 \u03bcg\/ml). Omadacycline was less active\n            <jats:italic>in vitro<\/jats:italic>\n            than ciprofloxacin (CIP) against\n            <jats:named-content content-type=\"genus-species\">Y. pestis<\/jats:named-content>\n            (CIP MIC\n            <jats:sub>90<\/jats:sub>\n            of 0.03 \u03bcg\/ml) but was more potent\n            <jats:italic>in vitro<\/jats:italic>\n            against\n            <jats:named-content content-type=\"genus-species\">B. anthracis<\/jats:named-content>\n            (CIP MIC\n            <jats:sub>90<\/jats:sub>\n            of 0.12 \u03bcg\/ml). In the mouse model of infection, the survival curves for all treatment cohorts differed significantly from the vehicle control (\n            <jats:italic>P<\/jats:italic>\n            = 0.004). The median survival for the vehicle-treated controls was 6 days postchallenge, while all antibiotic-treated mice survived the entire study. Omadacycline treatment with 5, 10, or 20 mg\/kg of body weight twice daily for 14 days had significant efficacy over the vehicle control in the treatment of aerosolized\n            <jats:named-content content-type=\"genus-species\">B. anthracis<\/jats:named-content>\n            . Additionally, for postexposure prophylaxis treatment of mice infected with\n            <jats:named-content content-type=\"genus-species\">Y. pestis<\/jats:named-content>\n            , the survival curves for omadacycline (40 mg\/kg twice daily), ciprofloxacin, and doxycycline cohorts differed significantly from the vehicle control (\n            <jats:italic>P<\/jats:italic>\n            &lt; 0.0001). Omadacycline is potent and demonstrates efficacy against both\n            <jats:named-content content-type=\"genus-species\">B. anthracis<\/jats:named-content>\n            and\n            <jats:named-content content-type=\"genus-species\">Y. pestis<\/jats:named-content>\n            . The well-characterized oral and intravenous pharmacokinetics, safety, and tolerability warrant further assessment of the potential utility of omadacycline in combating these serious biothreat organisms.\n          <\/jats:p>","DOI":"10.1128\/aac.02434-16","type":"journal-article","created":{"date-parts":[[2017,2,22]],"date-time":"2017-02-22T01:30:22Z","timestamp":1487727022000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":30,"title":["<i>In Vitro<\/i>\n            and\n            <i>In Vivo<\/i>\n            Activity of Omadacycline against Two Biothreat Pathogens, Bacillus anthracis and Yersinia pestis"],"prefix":"10.1128","volume":"61","author":[{"given":"Judith","family":"Steenbergen","sequence":"first","affiliation":[{"name":"Paratek Pharmaceuticals, King of Prussia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Ken","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Paratek Pharmaceuticals, King of Prussia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynda L.","family":"Miller","sequence":"additional","affiliation":[{"name":"Bacteriology Division, U.S. Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie A.","family":"Halasohoris","sequence":"additional","affiliation":[{"name":"Bacteriology Division, U.S. Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy R.","family":"Hershfield","sequence":"additional","affiliation":[{"name":"Bacteriology Division, U.S. Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-28994-1_15"},{"key":"e_1_3_2_3_2","first-page":"269","article-title":"Lessons to be learned from recent biosafety incidents in the United States","volume":"17","author":"Weiss S","year":"2015","unstructured":"Weiss S YitzhakiSShapiraSC. 2015. Lessons to be learned from recent biosafety incidents in the United States. Isr Med Assoc J17:269\u2013273.","journal-title":"Isr Med Assoc J"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid0802.010164"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.2217\/fmb.12.116"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00181-15"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40475-015-0042-2"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.283.17.2281"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.281.18.1735"},{"key":"e_1_3_2_10_2","volume-title":"U.S","author":"FDA Drug Safety Communication","year":"2016","unstructured":"FDA Drug Safety Communication. 2016. FDA advises restricting fluoroquinolone antibiotic use for certain uncomplicated infections; warns about disabling side effects that can occur together. U.S. FDA,Washington, DC."},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01066-13"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01536-15"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01242-13"},{"key":"e_1_3_2_14_2","volume-title":"Abstr 55th Intersci Conf Antimicrob Agents Chemother","author":"DuBois J","year":"2015","unstructured":"DuBois J DuboisMMartelJ-FTanakaSK. 2015. In vitro activity of omadacycline against Legionella pneumophila. Abstr 55th Intersci Conf Antimicrob Agents Chemother,abstr F-770."},{"key":"e_1_3_2_15_2","volume-title":"Abstr 55th Intersci Conf Antimicrob Agents Chemother","author":"Flamm RK","year":"2015","unstructured":"Flamm RK RhombergPRHubandMDFarrellDJ. 2015. Activity of omadacycline tested against Enterobacteriaceae causing urinary tract infections from a global surveillance program (2014). Abstr 55th Intersci Conf Antimicrob Agents Chemother,abstr C-614."},{"key":"e_1_3_2_16_2","volume-title":"Abstr 55th Intersci Conf Antimicrob Agents Chemother","author":"Flamm RK","year":"2015","unstructured":"Flamm RK RhombergPRHubandMDFarrellDJ. 2015. Activity of omadacycline tested against Streptococcus pneumoniae from a global surveillance program (2014). Abstr 55th Intersci Conf Antimicrob Agents Chemother,abstr C-554."},{"key":"e_1_3_2_17_2","volume-title":"Abstr 55th Intersci Conf Antimicrob Agents Chemother","author":"Flamm RK","year":"2015","unstructured":"Flamm RK RhombergPRHubandMDFarrellDJ. 2015. Activity of omadacycline tested against Staphylococcus aureus from a global surveillance program (2014). Abstr 55th Intersci Conf Antimicrob Agents Chemother,abstr F-289."},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.26226\/morressier.56d6be7ad462b80296c97dee"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01050-06"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid0810.020353"},{"key":"e_1_3_2_21_2","first-page":"1002","article-title":"Anthrax as a biothreat and our current understanding of this disease","volume":"1","author":"K\u00f6nig R","year":"2013","unstructured":"K\u00f6nig R . 2013. Anthrax as a biothreat and our current understanding of this disease. J Immunol Clin Res1:1002.","journal-title":"J Immunol Clin Res"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201102-0209CI"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.12998\/wjcc.v3.i1.20"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-144-4-200602210-00009"},{"key":"e_1_3_2_25_2","volume-title":"Development of in vitro susceptibility testing criteria and quality control parameters; approved guideline","author":"Clinical and Laboratory Standards Institute","year":"2008","unstructured":"Clinical and Laboratory Standards Institute. 2008,Development of in vitro susceptibility testing criteria and quality control parameters; approved guideline,3rd ed. Document M23-A3E. Clinical and Laboratory Standards Institute,Wayne, PA.","edition":"3"},{"key":"e_1_3_2_26_2","volume-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard","author":"Clinical and Laboratory Standards Institute","year":"2012","unstructured":"Clinical and Laboratory Standards Institute. 2012. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard,9th ed. Document M07-A9 (ISBN 1-56238-784-7). Clinical and Laboratory Standards Institute,Wayne, PA.","edition":"9"},{"key":"e_1_3_2_27_2","volume-title":"Performance standards for antimicrobial susceptibility testing","author":"Clinical and Laboratory Standards Institute","year":"2013","unstructured":"Clinical and Laboratory Standards Institute. 2013. Performance standards for antimicrobial susceptibility testing; 23rd informational supplement. CLSI Document M100-S23 (ISBN 1-56238-865-7). Clinical and Laboratory Standards Institute,Wayne, PA."},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04548-14"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(18)62213-6"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.3.675"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/0021-8502(73)90006-2"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vascn.2003.07.001"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajplegacy.1947.150.1.70"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02434-16","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02434-16","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T20:53:46Z","timestamp":1645476826000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.02434-16"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["10.1128\/AAC.02434-16"],"URL":"https:\/\/doi.org\/10.1128\/aac.02434-16","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"2016-11-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-02-05","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-04-24","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e02434-16"}}